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a b s t r a c t
Background: There are no reports on hyponatremia and acute kidney injury (AKI) involved
in the course of HIV-related toxoplasmic encephalitis (TE). The main objective of this study
was to describe the occurrence of hyponatremia and its relationship with AKI and mortality
in HIV-related toxoplasmic encephalitis (TE).
Methods: This was a retrospective cohort study on patients with HIV-related TE. AKI was
considered only when the RIFLE (risk, injury, failure, loss, end-stage) criterion was met,
after the patient was admitted.
Results: A total of 92 patients were included, with a mean age of 36± 9 years. Hyponatremia
at admission was observed in 43 patients (46.7%), with AKI developing in 25 (27.1%) patients
during their hospitalization. Sulfadiazine was the treatment of choice in 81% of the cases.
Death occurred in 13 cases (14.1%). Low serum sodium level correlated directly with AKI and
mortality. Male gender (OR 7.89, 95% CI 1.22-50.90, p= 0.03) and hyponatremia at admission
(OR 4.73, 95% CI 1.22-18.30, p= 0.02) were predictors for AKI. Independent risk factors for
deathwere AKI (OR 8.3, 95%CI 1.4-48.2, p < 0.0001) and hyponatremia (OR 9.9, 95%CI 1.2-96.3,p<0.0001).
Conclusion: AKI and hyponatremia are frequent in TE. Hyponatremia on admission is highly
associated with AKI and mortality.
Although scarcely studied in TE, alterations in serum
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroductionToxoplasmic encephalitis (TE) is the most frequent neurologic
disorder in patients with advanced human immunodeﬁciency
virus (HIV) infection.1,2 Low CD4+ T-cell count and lack of
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sodium regulation constitute a common feature in neuro-
logic disorders.4 Neurologic-associated hyponatremia could
be due to the syndrome of inappropriate antidiuretic hormone


















































lbraz j infect d i s .
ecretion (SIADH), also known as cerebral salt-wasting syn-
rome, which is clinically challenging to diagnose with
ccuracy.5 Hyponatremia per se is associated with a reserved
rognosis.6 However, the associationwith TE is not fully estab-
ished, with studies suggesting that hyponatremia may be a
ere indicator of the severity of illness.7
In the general HIV-infected population, risk factors for
eveloping acute kidney injury (AKI) are well established (hep-
titis virus C infection, opportunistic infections, nephrotoxic
rugs), as well as their implications on prognosis.8,9 HIV-
nfected patients with TE are, in theory, at increased risk for
eveloping AKI, mainly because the treatment for TE consists
f using a nephrotoxic drug, sulfadiazine.10
Sulfadiazine is a short-acting sulfonamide derivative that
ndergoes acetylation in the liver to a variable degree (10% to
0%). Sulfadiazine-related nephrotoxicity is through crystal-
uria due to acidiﬁed urine, leading to tubular obstruction.11
lthough many published case reports describe sulfadiazine-
elated crystalluria and its association to AKI, incidence, risk
actors, and evolution remain unclear.
Moreover, in some studies, AKI has been independently
ssociated with hyponatremia, with the latter being consid-
red a consequence of the former. This study aimed to analyze
yponatremia in HIV-infected patients with TE, its temporal
elationship with AKI, and involved prognostic implications.
ethods
tudy design
his study was retrospective cohort study conducted at a ter-
iary and reference center for infectious diseases (Hospital São
osé de Doenc¸as Infecciosas) in the city of Fortaleza, Brazil.
IV-infected patients with TE diagnosis, from March 2002 to
ovember 2007 were included in the study. Patients with end-
tage renal disease undergoing maintenance dialysis were
xcluded. The study protocol was approved by the local Insti-
utional Ethics Committee, protocol number 021/2007, on 20
ugust 2007. Due to the retrospective nature of the study, the
nstitutional review board waived the participants’ informed
onsent.
ata collection
he clinical investigation included a reviewof all demographic
haracteristics, clinical signs, symptoms presented by each
atient upon hospital admission, and use of antiretroviral
rugs. Laboratory data included the assessment of serum
rea, creatinine, transaminases (AST, ALT), direct and indirect
ilirubin, lactate dehydrogenase (LDH), complete blood count,
D4+ T-cell count, HIV viral load, and urinalysis.
eﬁnitions
presumptive diagnosis of TE was made according to the
riteria proposed by the Centers for Disease Control and Pre-
ention, USA, which include recent onset of a focal neurologic
bnormality consistent with intracranial disease or a reduced
evel of consciousness; evidence by computed tomography or2;16(6):558–563 559
magnetic resonance imaging of a lesion exerting ‘a mass effect’
or a cranial radiographic image which is enhanced by inject-
ing a contrast medium; and the presence of serum antibodies
against Toxoplasma gondii or a successful clinical response to
appropriate therapy for toxoplasmosis.
Admission hyponatremia was considered only when the
patient presented a serum sodium concentration of less than
135 mEq/L at admission; severe hyponatremia was deﬁned
when the patient had a serum sodium concentration of less
than 125 mEq/L upon admission.
AKI was deﬁned according to the RIFLE criteria: risk (“R”)
when measured maximum serum creatinine (SCr) was 1.5
times greater than the basal SCr; injury (“I”) when the max-
imum SCr was twice the value of the basal SCr, or failure
(“F”) when maximum SCr was three times the value of the
basal SCr. According to the RIFLE criteria, if a patient basal
SCr is equal or greater than 4mg/dL, only an increment of
0.5mg/dL is sufﬁcient to classify thepatient in the “F” category.
No patients with loss, (“L”) or end-stage (“E”) were included in
the study. The basal SCr was considered to be that obtained
at admission. AKI was considered only if the SCr increment
occurred after hospital admission. Therefore, irrespective of
the patients’ SCr, an improvement after admission was not
considered as AKI. Urine outputwas not integrated in the clas-
siﬁcation according to the RIFLE criteria due to lack of recorded
information in the medical records. The estimated glomerular
ﬁtration rate (eGFR) was calculated using the simpliﬁed MDRD
equation. HIV-associated nephropathy (HIVAN) was not a pos-
sible diagnosis in the studied cases, since the patients had no
signiﬁcant proteinuria.
Treatment protocol
The ﬁrst line therapy for TE was a daily dose of pyrimetha-
nine 75-100mg over the ﬁrst three days, and a subsequent
daily dose of 25-50mg, plus oral sulfadiazine 500-1,000mg four
times a day, during fourweeks. Additionally, all patients under
treatment received a daily dose of folinic acid.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS) 17.0 program. Descriptive
statistics were expressed as mean±SD. The primary analysis
compared AKI to non-AKI patients, presence of hypona-
tremia on admission, and indicators of hospital mortality.
All variables were tested for a normal distribution using
the Kolmogorov-Smirnov test. Student’s t-test was used to
compare the means of the continuous variables of normally
distributed data. All categorical datawere tested using the chi-
squared test. Data related to the severity of hyponatremia on
admission were tested using the analysis of variance (ANOVA)
test; Tukey’s post hoc test was used for numerical values,
and the chi-squared test was used for trends in assessing
categorical data. Amultiple logistic regressionmodelwas con-
structed, and association measures were calculated (adjusted
odds ratio), with a 95% conﬁdence interval. Stepwise backward
elimination multivariate analysis was performed to inves-
tigate the independent risk factors for developing AKI and
for hospital mortality, which included factors presenting a
560 braz j infect d i s . 2012;16(6):558–563












Age (years) 37.5± 9.9 34.6± 8.5 0.15 36.7± 9.7 35.9± 9.0 0.70
Gender
Male 29 (67%) 33 (67%) 0.93 19 (76%) 47 (70%) 0.72
Female 11 (33%) 19 (33%) 6 (24%) 20 (29.8%)
Main symptom
Headache 19 (44.1%) 22 (44.8%) 0.89 9 (36%) 32 (47.7%) 0.25
Motor deﬁcit 5 (11.6%) 7 (14.2%) 2 (8%) 10 (14.9%)
Convulsion 11 (25.5%) 11 (22.4%) 4 (16%) 20 (29.8%)
Signs and symptoms
Fever 14 (32.5%) 7 (14.2%) 0.03 8 (32%) 16 (23.8%) 0.47
Weight loss 26 (50.4%) 18 (36.7%) 0.02 17 (68%) 31 (46.2%) 0.08
Vomiting 11 (25.5%) 11 (22.4%) 0.74 7 (28%) 16 (23.8%) 0.74
Diarrhea 17 (39.5%) 20 (40.8%) 0.85 11 (44%) 27 (40.2%) 0.83
Jaundice 1 (2.3%) 1 (2.0%) 0.93 1 (4%) 1 (1.4%) 0.47
Laboratory tests
Ur (mg/dL) 32.0± 28.5 24.6± 11.0 0.20 37.9± 34.6 24.7± 10.4 0.03
Cr (mg/dL) 0.7± 0.4 0.8± 0.3 0.08 0.8± 0.5 0.8± 0.3 0.70
Hb (g/dL) 10.4± 1.8 13.5± 14.2 0.19 13.7± 1.8 11.1± 2.0 0.30
White blood count (/mm3) 5005± 3441 4984± 2040 0.97 5095± 3849 5003± 2167 0.89
Platelets (/mm3) 229254± 3.1 187905± 1.0 0.45 255485± 3.8 181518± 1.0 0.19
AST (IU/L) 39.4± 19.5 37.5± 16.3 0.73 41.7± 18.0 39.8± 20.2 0.77
ALT (IU/L) 40.4± 22.7 47.7± 28.9 0.36 41.2± 22.0 47.5± 31.3 0.52
Albumin (g/dL) 2.8± 0.5 3.6± 0.3 0.01 2.9± 0.8 3.0± 0.5 0.87
Antiretroviral use 28 (65.1%) 26 (53%) 0.24 18 (72%) 40 (59.7%) 0.35
AKI 18 (41.8%) 7 (14.2%) 0.002 25 (100%) - -
Hyponatremia 43 (100%) - - 18 (72%) 20 (29.8%) 0.002
Death 11 (25.5%) 2 (4.0%) 0.0001 8 (32%) 3 (4.4%) 0.0001
eraseUr, urea; Cr, creatinine; Hb, hemoglobin; AST, aspartate aminotransf
t-test and Fisher’s exact test. Signiﬁcant p<0.05.
signiﬁcance level < 0.2% in the univariate analysis (Mann-
Whitney’s and chi-squared tests). p-values <0.05 were
considered to be statistically signiﬁcant.
Results
Patients
A total of 92 patients had a diagnosis of toxoplasmosis dur-
ing the study period. The gender ratio (men:women) was
3.5:1 and the mean age was 36.2 ± 9.0 years. Before admis-
sion, 59 (64%) patients were under highly active antiretroviral
therapy (HAART). The main drugs used in HAART were
zidovudine and lamivudine (48% each), efavirenz (30.4%), and
lopinavir/ritonavir and atazanavir (12% each). Other antiretro-
viral drugs used in less than 10% of the cases included:
tenofovir, stavudine, ritonavir, and abacavir. The mean CD4+
T cell count was 128± 82 cells/mm3. Six patients had asso-
ciated diabetes mellitus, while hypertension was present in
four patients. Initially, all patients received a sulfadiazine
and pyrimethanine-based therapy. In 15 patients, the treat-
ment was changed to clindamycin. The mean hospital stay
was 24± 19 days. The complete laboratory data are shown in
Table 1.; ALT, alanine aminotransferase; AKI, acute kidney injury; Student’s
Hyponatremia
Hyponatremia on admission was veriﬁed in 43 (46.7%)
patients, and severe hyponatremia (less than 125 mEq/L)
in ten cases (10.8%). Serum sodium upon admission was
137.9± 2.5mEq/L inpatientswithnormal range and129.1± 3.9
in hyponatremic patients (range 116-139 mEq/L), p < 0.001.
Patients admitted with hyponatremia reported a history of
recent weight loss and fever more frequently than normona-
tremic patients. AKI during hospital stay and mortality was
more frequent inhyponatremic patients, especially in patients
with severe hyponatremia (Fig. 1). Data showing the compar-
ison among the patients with and without hyponatremia are
shown in Table 1.
Mortality rate was higher in patients admitted with
hyponatremia, showing a stepwise increment according to the
severity of hyponatremia (Fig. 1).
Acute kidney injury
Only ﬁve patients had a GFR of less than 80mL/min/1.73m2at admission, whose renal function improved during their
hospital stay, thus it was possible to diagnose AKI at admis-
sion. During hospitalization, 25 patients (27.1%) developed
some degree of AKI, considering the SCr on admission as
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risk of dying in TE. In the present study, male gender andevels in patients with toxoplasmic encephalitis.
he baseline renal function. The distribution according to
IFLE category was: risk, seven patients; injury, 11; and failure,
even. No patient needed renal substitutive therapy. Mortality
ate was 32% among patients with any degree of AKI. Upon
ultivariate analysis, male gender (OR 7.890, 95% CI 1.223-
0.906, p=0.03) and hyponatremia on admission (OR 4.732,
5% CI 1.223-18.307, p=0.024) were independently related to
KI developed during hospital stay. A comparison among
atients with and without AKI is shown in Table 1.
actors related to hospital mortality
eath occurred in 13 cases (14.1%). As demonstrated inTable 2,
urvivors had comparable clinical and laboratory ﬁndings to
on-survivors, except but for a higher prevalence of hypona-
remia at admission, lower serum sodium (131.3± 7.4 vs.
35.2± 4.8mEq/L, p=0.02) and higher incidence of hospital-
cquired AKI. In multivariate analysis, hyponatremia upon
dmission (OR 4.73, 95% CI 1.22-18.3, p = 0.02) and male gender
OR 7.89, 95% CI 1.22-50.9, p = 0.03) were independent factors
elated to hospital mortality.
iscussion
he present study found important associations between
yponatremia, AKI and mortality in patients with TE. A sig-
iﬁcant proportion of patients presented hyponatremia (more
han 40% of cases) at hospital admission. AKI-development
nd mortality were both associated with the severity of
yponatremia. The data also disclosed an independent rela-
ionship between hospital-acquired AKI and mortality in this
opulation. This is the ﬁrst study to evidence these ﬁndings in
E and,moreover, to describe a temporal relationship between
yponatremia and posterior AKI development.
There are reports on the literature describing the involve-
ent of kidneys in animals infected with toxoplasmosis.1,12
ne of the few articles on this topic reports a case of nephrotic
yndrome in an immunocompetent patient with generalized
oxoplasmosis, but with normal renal function, who had com-
lete recovery with supportive therapy.132;16(6):558–563 561
Infection with T. gondii rarely complicates to AKI,
which is described only as a consequence of sulfadiazine
crystalluria.14,15 However, in the present study, a signiﬁ-
cant association between sulfadiazine use and AKI was not
observed. Therefore, it is suggested that other mechanisms
may be involved in toxoplasmosis-associated AKI, which need
to be elucidated. AKI is a frequent complication in patients
with infectious diseases,16,17 which could also occur in T. gondii
infection.
The majority of patients in the present cohort were
on HAART (64%). The mean CD4+ T-cell count was low.
All patients were treated with sulfadiazine. In HIV-infected
patients, levels of CD4+ T-cell counts inversely correlate
with reactivation of T. gondii infection, and can cause severe
histopathological changes.18 Low CD4+ T-cell count could
explain the severe complications observed in this study.
Hyponatremia on admission was frequently observed in
this study sample (46.7%), and was severe in 10.8% of the
cases. Themost common causes of hyponatremia among hos-
pitalized patients with toxoplasmosis are SIADH and use of
diuretics.19 Hyponatremia is the most common electrolyte
disorder in clinical practice, known to be associated with
increased mortality in patients with different settings.20,21
In thepresent study, patientswithhyponatremia onadmis-
sion had a history of recent weight loss and fever more
frequently than normonatremic patients. Hyponatremia is
seldom described in toxoplasmosis, and can be the presenting
feature in some cases.22 As reported in the literature, it occurs
in approximately 10% of children with acute central nervous
system diseases without renal dysfunction or prior use of
diuretics, where complications could be due to SIADH or cere-
bral salt wasting.23 It is suggested that similar mechanisms
are involved in patients with TE. In animals with toxoplasmo-
sis, hyponatremia has also been described in one fatal case.24
However, the precise cause of hyponatremia in toxoplasmosis
remains unclear. There are descriptions of SIADH and dia-
betes insipidus in association with this parasitic infection,
which could in part justify the occurrence of this electrolyte
abnormality.25
In the present study, hyponatremia occurred before the
development of AKI, and it proved to be an important risk fac-
tor for AKI. A possiblemechanism for this ﬁnding could be that
hyponatremia triggers release of ADH, leading to increased
urinary concentration, which in turn predisposes to sulfadi-
azine crystal deposition. One of the limitations of the present
study is that a majority of the patients did not have urinal-
ysis, which would have allowed studying the urine sediment
for crystals.
AKI is an important risk factor for death. In their work,
Macedo et al.26 showed that oliguria lasting for more than 12h
and of more than three episodes had an increased real risk for
mortality. In this sample, mortality in patients presenting any
degree ofAKIwas 32%,whichwas signiﬁcantly higher than the
overall mortality (14%). Similar mortality rates, varying from
15% to 27%, have been reported.27,28 Nonetheless, currently,
no report has associated AKI and hyponatremia to increaseadmission hyponatremia were independently related to AKI
development. Survivors had comparable clinical and labora-
tory ﬁndings to non-survivors, except for higher prevalence of
562 braz j infect d i s . 2012;16(6):558–563







Age (years) 36.2± 9.0 36.0± 9.6 0.95
Length of hospital stay (days) 22± 17 32± 27 0.10
Gender
Male 59 (74.7%) 9 (69.2%) 0.73
Female 20 (25.3%) 4 (30.8%)
Main symptom
Headache 37 (46.8%) 6 (46.1%) 1.0
Motor deﬁcit 12 (15.1%) 0
Convulsion 21 (26.5%) 3 (23%)
Signs and symptoms
Fever 19 (24%) 5 (38.4%) 0.31
Weight loss 43 (54.4%) 6 (46.1%) 0.76
Vomiting 21 (26.5%) 3 (23%) 1.0
Diarrhea 36 (45.5%) 3 (23%) 0.22
Jaundice 1 (1.2%) 1 (7.6%) 0.26
Laboratory tests
Ur (mg/dL) 29± 22 25± 7.2 0.64
Cr (mg/dL) 0.8± 0.4 0.7± 0.2 0.43
Hb (g/dL) 12± 10 10± 1.4 0.66
White blood count (/mm3) 5034± 2839 5083± 2319 0.95
Platelets (/mm3) 214006± 2.4 168056± 1.0 0.52
AST (IU/L) 40± 19 39± 19 0.93
ALT (IU/L) 47± 30 37± 22 0.35
Albumin (g/dL) 3.1± 0.7 2.9± 0.5 0.61
Na+ (mEq/L) 135± 4.7 131± 7.4 0.02
K+ (mEq/L) 4.2± 0.7 4.7± 0.8 0.04
Antiretroviral use 50 (63.2%) 9 (69.2%) 0.76
Hyponatremia 28 (35.4%) 12 (92.3%) <0.0001
AKI 17 (21.5%) 8 (61.5%) 0.001
sferas
ct tesUr, urea; Cr, creatinine; Hb, hemoglobin AST, aspartate aminotran
potassium; AKI, acute kidney injury; Student’s t-test and Fisher’s exa
hyponatremia at admission, lower serum sodium, and higher
incidence of AKI.
In this study serum sodium levels were signiﬁcantly asso-
ciated with mortality, evidencing that hyponatremia per se
increased mortality, which is different from what has recently
been suggested by others,7 who stated that patients died
“with” and not “due to” hyponatremia. Another recent study
evidenced that outpatients with chronic heart failure who
had hyponatremia presented increased mortality, with this
electrolyte disturbance being an independent predictor of all-
cause mortality.29 Even small increases in sodium levels are
associated with higher risk of death.30 Hyponatremia can be a
predictor of death in TE because it indirectly reﬂects a proba-
ble,more severe neurological lesion. As amatter of fact, severe
or acute hyponatremia can cause life-threatening cerebral
edema.6 Thus, hyponatremia can also be a marker of disease
severity, since it can be a sign of the presence of important
physiologic derangements.6
In summary, AKI and hyponatremia are common events
in toxoplasmic encephalitis. Admission hyponatremia is
highly associated with AKI and mortality. As patients pre-
sented hyponatremia at admisson and developed AKI during
hospitalization, hyponatremia might represent an accessi-
ble and reliable marker for an increased risk of AKI ande; ALT, alanine aminotransferase; Na+, serum sodium; K+, serum
t. Signiﬁcant p<0.05.
perhaps of death. Increased kidney monitoring, and limited
use of nephrotoxic drugs or radiographic contrast agent are
suggested for these patients. Hyponatremia, a potentially
treatable electrolyte abnormality, is a crucial event in this pop-
ulation. Itmust be identiﬁed and correctly treated, considering
that itmay per sebe associatedwith cerebral edema, coma, and
death in these patients.
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